RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Mandip Sachdeva to Cell Line, Tumor

This is a "connection" page, showing publications Mandip Sachdeva has written about Cell Line, Tumor.
Connection Strength

1.305
  1. Aare M, Padakanti SC, Singh M. In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts. AAPS PharmSciTech. 2025 Sep 11; 26(7):227.
    View in: PubMed
    Score: 0.143
  2. Aare M, Lazarte JMS, Muthu M, Rishi AK, Singh M. Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. Drug Deliv Transl Res. 2026 Feb; 16(2):693-710.
    View in: PubMed
    Score: 0.142
  3. Nathani A, Sun L, Li Y, Lazarte J, Aare M, Singh M. Targeting EGFR-TKI resistance in lung cancer: Role of miR-5193/miR-149-5p loaded NK-EVs and Carboplatin combination. Int J Pharm. 2025 Apr 30; 675:125573.
    View in: PubMed
    Score: 0.139
  4. Nathani A, Khan I, Tanimoto MH, Mej?a JAA, DE Miranda AM, Rishi A, Dev S, Bastos JK, Singh M. Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis. Anticancer Res. 2024 Oct; 44(10):4175-4188.
    View in: PubMed
    Score: 0.134
  5. Kommineni N, Nottingham E, Bagde A, Patel N, Rishi AK, Dev SRS, Singh M. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. Eur J Pharm Biopharm. 2021 Jan; 158:172-184.
    View in: PubMed
    Score: 0.102
  6. Patel K, Doddapaneni R, Patki M, Sekar V, Bagde A, Singh M. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. AAPS PharmSciTech. 2019 Mar 04; 20(3):135.
    View in: PubMed
    Score: 0.091
  7. Andey T, Bora-Singhal N, Chellappan SP, Singh M. Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors. Nanomedicine. 2019 06; 18:31-43.
    View in: PubMed
    Score: 0.091
  8. Doddapaneni R, Patel K, Chowdhury N, Singh M. Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. Sci Rep. 2017 Nov 20; 7(1):15824.
    View in: PubMed
    Score: 0.083
  9. Kutlehria S, Behl G, Patel K, Doddapaneni R, Vhora I, Chowdhury N, Bagde A, Singh M. Cholecalciferol-PEG Conjugate?Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer. AAPS PharmSciTech. 2018 Feb; 19(2):792-802.
    View in: PubMed
    Score: 0.082
  10. Chowdhury N, Vhora I, Patel K, Doddapaneni R, Mondal A, Singh M. Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer. Pharm Res. 2017 Nov; 34(11):2371-2384.
    View in: PubMed
    Score: 0.082
  11. Doddapaneni R, Patel K, Chowdhury N, Singh M. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp Cell Res. 2016 08 01; 346(1):65-73.
    View in: PubMed
    Score: 0.075
  12. Patel K, Chowdhury N, Doddapaneni R, Boakye CHA, Godugu C, Singh M. Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. J Pharm Sci. 2015 Dec; 104(12):4417-4426.
    View in: PubMed
    Score: 0.071
  13. Godugu C, Doddapaneni R, Patel AR, Singh R, Mercer R, Singh M. Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res. 2016 Jan; 33(1):137-54.
    View in: PubMed
    Score: 0.071
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support